Latest Articles
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening - Nature
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening Nature
Published: March 3, 2026, 10:36 a.m.
6 Tips for Going Through Endometrial Cancer Treatment - Cleveland Clinic Health Essentials
6 Tips for Going Through Endometrial Cancer Treatment Cleveland Clinic Health Essentials
Published: March 3, 2026, 8:30 a.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World
Published: March 2, 2026, 6:50 p.m.
GLP-1–Progestin and Endometrial Cancer Risk - Conexiant
GLP-1–Progestin and Endometrial Cancer Risk Conexiant
Published: March 2, 2026, 5:01 p.m.
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks
Published: Feb. 27, 2026, 7:47 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView
Published: Feb. 27, 2026, 3:34 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Published: Feb. 27, 2026, 3:24 p.m.
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView
Published: Feb. 27, 2026, 2:50 p.m.
Link copied to clipboard!